Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial
Hedy Lee Kindler, Silvia Novello, Alessandra Bearz et al. · The Lancet Oncology · 2022
Cited by 68 works. doi:10.1016/s1470-2045(22)00061-4
Authors
- Hedy Lee Kindler
- Silvia Novello
- Alessandra Bearz
- Giovanni Luca Ceresoli
- Joachim G.J.V. Aerts
- James F. Spicer
- Paul Taylor
- Kristiaan Nackaerts
- Alastair Greystoke
- Ross R. Jennens
- Luana Calabrò
- Jacobus A. Burgers
- Armando Santoro
- S. Cedrés
- Piotr Serwatowski
- Santiago Ponce
- Jan P. van Meerbeeck
- Anna K. Nowak
- George R. Blumenschein
- Jonathan Siegel
References
- Modified RECIST criteria for assessment of response in malignant pleural mesothelioma
- Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
- Direct detection of early-stage cancers using circulating tumor DNA
- Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
- Integrative Molecular Characterization of Malignant Pleural Mesothelioma
- Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline
- Phase III Trial of Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma
- Mesothelin targeted cancer immunotherapy
- A requirement for breast-cancer-associated gene 1 (BRCA1) in the spindle checkpoint
- Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial